Cargando…

Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch

Understanding the underlying molecular interaction during a therapy switch from lopinavir (LPV) to darunavir (DRV) is essential to achieve long-term virological suppression. We investigated the kinetic and structural characteristics of multidrug-resistant South African HIV-1 subtype C protease (HIV-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eche, Simeon, Kumar, Ajit, Sonela, Nelson, Gordon, Michelle L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064090/ https://www.ncbi.nlm.nih.gov/pubmed/33805099 http://dx.doi.org/10.3390/biom11040489

Ejemplares similares

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
por: Jose, Sophie, et al.
Publicado: (2017)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
por: Ucciferri, Claudio, et al.
Publicado: (2016)

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance
por: Nakashima, Masaaki, et al.
Publicado: (2016)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in Cambodia
por: Limsreng, Setha, et al.
Publicado: (2016)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
por: Henrivaux, Philippe, et al.
Publicado: (2010)

Darunavir-Resistant HIV-1 Protease Constructs Uphold a Conformational Selection Hypothesis for Drug Resistance
por: Liu, Zhanglong, et al.
Publicado: (2020)

Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy
por: Vesterbacka, Jan, et al.
Publicado: (2013)

Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study
por: Elmekaty, Eman Zeyad I., et al.
Publicado: (2022)

Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
por: Di Castelnuovo, Augusto, et al.
Publicado: (2021)

Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014)

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa
por: Wallis, Carole L., et al.
Publicado: (2011)

Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam
por: Lan, Nguyen Thi Ngoc, et al.
Publicado: (2014)

The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients
por: Kredo, T., et al.
Publicado: (2016)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies
por: Kala, Smriti, et al.
Publicado: (2020)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting
por: Clumeck, Nathan, et al.
Publicado: (2014)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
por: Rossetti, Barbara, et al.
Publicado: (2017)

Similar plasma lipidomic profile in people living with HIV treated with a darunavir-based or an integrase inhibitor-based antiretroviral therapy
por: Mena, Alvaro, et al.
Publicado: (2019)

The L33F darunavir resistance mutation acts as a molecular anchor reducing the flexibility of the HIV-1 protease 30s and 80s loops
por: Kuiper, Benjamin D., et al.
Publicado: (2015)

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study
por: Gori, Andrea, et al.
Publicado: (2020)

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
por: Ranzenigo, Martina, et al.
Publicado: (2022)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Protease Inhibitor Anti-HIV, Lopinavir, Impairs Placental Endocrine Function
por: Fraichard, Camille, et al.
Publicado: (2021)

Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients
por: Eljaaly, Khalid, et al.
Publicado: (2020)

Week 120 Efficacy of Tenofovir, Lamivudine and Lopinavir/r-Based Second-Line Antiretroviral Therapy in Treatment-Experienced HIV Patients
por: Han, Yang, et al.
Publicado: (2015)

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
por: Naiker, Suhashni, et al.
Publicado: (2014)

Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Evaluation of novel protease inhibitors against darunavir‐resistant variants of HIV type 1
por: Inoue, Mari, et al.
Publicado: (2016)

The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms
por: Gao, Xiaobo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ca19s3bikhhomofk0saek4htd0